Answers are grounded in this paper and cite their sources.
Background: Pertuzumab, an anti-human epidermal growth factor receptor 2/3 (HER2/HER3) monoclonal antibody, has been demonstrated to be effective in the treatment of HER2-positive breast cancer. It was initially licensed in Ireland for the treatment of metastatic breast cancer in 2015, but is now also used in the neoadjuvant and adjuvant settings for primary breast cancer with high-risk features for recurrence. The aim was to assess current prescribing practices of pertuzumab (Perjeta) in HER2+ breast cancer patients in one of the eight Irish designated cancer surgical centres, which is also an Organisation of European Cancer Institutes (OECI)-accredited cancer centre.
No takes yet. Share an insight, caveat, or question.
Hembrecht et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: